Topiramate

Epilepsia

Volumn 40, Issue SUPPL. 5, 1999, Pages s71-s80

  Glauser, Tracy A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Antiepileptic drugs; Clinical trials; Epilepsy; Topiramate

Indexed keywords

TOPIRAMATE;

ANTICONVULSANT ACTIVITY; ATAXIA; CLINICAL TRIAL; CONFUSION; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDUCED DISEASE; FATIGUE; FOCAL EPILEPSY; HUMAN; LENNOX GASTAUT SYNDROME; NEPHROLITHIASIS; NONHUMAN; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; TONIC CLONIC SEIZURE; VERTIGO;

EID: 0032872031     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00922.x     Document Type: Review

References (63)

1. Reife R. Topiramate: a novel antiepileptic agent. In: Shorvon S, Dreifuss F, Fish D, Thomas D, eds. Treatment of epilepsy. Oxford: Blackwell Science, 1996;471-81.
2. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-24.
3. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
4. Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43.
5. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90.
6. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology 1996;46:1678-83.
7. Reife R, Pledger G, Lim P, Karim R. Topiramate: pooled analysis of six placebo-controlled trials [Abstract] Epilepsia 1996;37(suppl 4):74.
8. Rosenfeld WE, Sachdeo RC, Faught RE, Privitera M. Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: retrospective survey of open-label treatment. Epilepsia 1997;38(suppl 1):S34-6.
9. Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia 1997;38:294-300.
10. Glauser TA, Sachdeo RC, Ritter F, Reife R, Lim P. Topiramate in Lennox Gastaut Syndrome: a double blind trial [Abstract]. Neurology 1997;48:1729.
11. Elterman R, Glauser TA, Wyllie E, Reife R, Wu S-C, and the Topiramate YP study group. A double-blind, randomized trial of topiramate as adjunctive therapy for partial onset seizures in children. Neurology 1999;52:1338-44.
12. Biton V, Montouris GD, Riviello JD, Reife R, and The Topiramate YTC Study Group. Topiramate as add-on therapy in generalized seizures of non-focal origin. Ann Neurol 1997;42:502-3.
13. Glauser TA. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998;39:1324-8.
14. Glauser TA. Topiramate. Semin Pediatr Neurol 1997;4:34-42.
15. Glauser TA. Topiramate. In: Pellock J, ed. Pediatric epilepsy [in press].
16. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994; 35:450-60.
17. Maryanoff BE, Nortey SO, Gardocki JF, Shank RP, Dodgson SP. Anticonvulsant O-alkyl sulfamates. 2,3:4,5-bis-O-(1-methyl-ethylidene)-B-D-fructopyranose sulfamate and related compounds. J Med Chem 1987;30:880-7.
18. Coulter DA, Sombati S, DeLorenzo RJ. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons [Abstract]. Epilepsia 1993;34(suppl 2):123.
19. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997;28:167-79.
20. Brown SD, Wolf HH, Swinyard EA, Twyman RE, White HS. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia 1993;34(suppl 2):122-3.
21. White HS, Brown SD, Skeen GA, Twyman RE. The investigational anticonvulsant topiramate potentiates GABA-evoked currents in mouse cortical neurons [Abstract]. Epilepsia 1995;36 (suppl 4):34.
22. Seven L, Coulter DA, Sombati S, De Lorenzo RJ. Topiramate selectively blocks kainate currents in cultured hippocampal neurons [Abstract]. Epilepsia 1995;36(suppl 4):38.
23. White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997;38(suppl 1):S9-17.
24. Wauquier A, Zhou S. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 1996;24:73-7.
25. Nakamura J, Tamura S, Kanta T, et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol 1994;254:83-9.
26. Edmonds H, Jiang D, Zhang YP, Vaught JL. Topiramate in rat model of post traumatic epilepsy [Abstract]. Epilepsia 1991;32 (suppl 3):15.
27. Hersey SJ, High WL. On the mechanism of acid secretory inhibition by acetazolamide. Biochim Biophys Acta 1971;233:604-9.
28. Cho CH, Chen SM, Chen SW, et al. Pathogenesis of gastric ulceration produced by acetazolamide in rats. Digestion 1984;29:5-11.
29. Ryberg B, Bishop AE, Bloom SR, et al. Omeprazole and ranitidine, antisecretagogues with different modes of action, are equally effective in causing hyperplasia of enterochromaffin-like cells in rat stomach. Regul Peptides 1989;2:235-46.
30. Molon-Noblot S, Boussiquet-Leroux C, Owen RA, et al. Rat urinary bladder hyperplasia induced by oral administration of carbonic anhydrase inhibitors. Toxicol Pathol 1992;20:93-102.
31. Hirsch KS, Scott WJ, Hurley LS. Acetazolamide teratology; The presence of carbonic anhydrase during the sensitive stage of rat development [Abstract]. Teratology 1973;17:38A.
32. Scott WJ, Hirsch KS, DeSesso JM, Wilson JG. Comparative studies on acetazolamide teratogenesis in pregnant rats, rabbits, and rhesus monkeys. Teratology 1981;24:37-42.
33. Nakatsuka T, Komatsu T, Fujii T. Axial skeletal malformations induced by acetazolamide in rabbits. Teratology 1992;45:629-36.
34. Doose DR, Walker SA, Gisclon LG, Nayak RK. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996;36:884-91.
35. Nayak RK, Gisclon LG, Curtin CA, Benet LZ. Estimation of the absolute bioavailability of topiramate in humans without intravenous data [Abstract]. J Clin Pharmacol 1994;34:1029.
36. Easterling DE, Zakszewski T, Moyer MD, Margul BL, Marriott TB, Nayak RK. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans [Abstract]. Epilepsia 1988;29:662.
37. Johannessen SI. Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Epilepsia 1997;38(suppl 1):S18-23.
38. Gisclon LG, Riffitts JM, Sica DA, Gehr T, Ruddley J. The pharmacokinetics (PK) of topiramate (T) in subjects with renal impairment (RI) as compared to matched subjects with normal renal function (NRF) [Abstract]. Pharm Res 1993;10(suppl 10):S397.
39. Perucca E. Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. Epilepsia 1996;37(suppl 2):S8-13.
40. Gisclon LG, Curtin CR, Kramer LD. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin®) and topiramate (Topamax™) in epileptic patients on monotherapy, and during combination therapy [Abstract]. Epilepsia 1994;35(suppl 8):54.
41. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:774-80.
42. Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997;38:324-33.
43. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997;38:317-23.
44. Liao S, Palmer M. Digoxin and topiramate drug interaction study in male volunteers [Abstract]. Pharm Res 1993;10(suppl 10):S405.
45. Rosenfeld WE, Doose DR, Walker SA, Baldassarre J, Reife R. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol 1999;20:339-44.
46. Glauser TA, Miles MV, Tang P, Clark P, McGee K, Doose DR. Topiramate pharmacokinetics in infants. Epilepsia 1999;40:788-91.
47. Reife R, Pledger G, Lim P, Karim R. Patients achieving 75% and 100% seizure reductions in double-blind trials of topiramate [Abstract]. Epilepsia 1997;38(suppl 3):59.
48. Reife RA, Pledger GW. Topiramate as adjunctive therapy in refractory partial epilepsy: pooled analysis of data from five double-blind, placebo-controlled trials. Epilepsia 1997;38(suppl 1):S31-3.
49. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996;313: 1169-74.
50. Chadwick DW. An overview of the efficacy and tolerability of new antiepileptic drugs. Epilepsia 1997;38(suppl 1):S59-62.
51. Elferink AJ, Van Zwieten-Boot BJ. Analysis based on number needed to treat shows differences between drugs studied [Letter]. BMJ 1997;314:603.
52. Biton V, Montouris GD, Riviello JD, Reife R, and The Topiramate YTC Study Group. Efficacy and safety of topiramate in generalized tonic clonic seizures of non-focal origin. Epilepsia 1997;38: 206-7.
53. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37(suppl 2):S18-22.
54. Edwards KR, Kamin M, and the Topiramate TPS-TR Study Group. The beneficial effect of slowing the initial titration rate of topiramate [Abstract]. Neurology 1997;48(suppl 2):A39.
55. Wasserstein AG, Rak I, Reife RA. Nephrolithiasis during treatment with topiramate [Abstract]. Epilepsia 1995;36(suppl 3):S153.
56. Gilliam FG, Veloso F. Tolerability of topiramate as monotherapy in patients with recently diagnosed partial epilepsy [Abstract]. Epilepsia 1998;39(suppl 6):56.
57. Hauser WA. Seizure disorders: the changes with age. Epilepsia 1992;33(suppl 4):S6-14.
58. O'Donohoe NV. Epilepsies of childhood. 3rd ed. Oxford: Butterworth-Heineman, 1994:1-5.
59. Glauser TA. Topiramate use in pediatric patients. Can J Neurol Sci 1998;25:S8-12.
60. Glauser TA, Elterman R, Wyllie E. Long-term topiramate therapy in children with partial onset seizures. Neurology 1998;50:A99-100.
61. Glauser TA, Sachdeo RC, Ritter FJ, Reife R, Lim P. A double blind trial of topiramate in Lennox Gastaut syndrome (LGS) [Abstract]. Epilepsia 1997;38(suppl 3):131.
62. Glauser TA, Sachdeo RC, Ritter FJ, Reife R, Lim P. Topiramate as adjunctive therapy in Lennox Gastaut syndrome [Abstract]. Epilepsia 1997;38(suppl 8):207.
63. Ritter FJ, Glauser TA, Sachdeo RC, Wu SC. Topiramate as long term therapy in Lennox Gastaut syndrome [Abstract]. Neurology 1998;50:A312